Research Journal of Pharmacology and Pharmacodynamics

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Current Scenario in Coronary Stenting–A Review


Affiliations
1 Department of Pharmacy, JJT University, Vidyanagari, Churu Jhunjhunu Road, Chudela, District-Jhunjhunu–333001, Rajasthan, India
     

   Subscribe/Renew Journal


In this review article many research and review article on coronary stent has been reviewed thoroughly and prepared a review on the same basis. Percutaneous Coronary Interventions refers to both non-stenting procedures and stent interventions. Various types of stents are available in both Bare Metal Stent (BMS) as well as Drug Eluting Stent (DES). Various safety and efficacy studies have been performed to compare BMS and DES with variety of variables. Many studies favor BMS as a good option at low cost. However in the support of DES, many studies results show it's not inferior in term of safety than BMS. Even there are data available for comparative studies between BMS and DES for effectiveness by assessing Major Adverse Cardiac Event (MACE). Studies prove non inferiority of DES compared to BMS. Cost of DES is higher than BMS, in general, but Pharmacoeconomical Studies indicate that DES has greater ratio of effectiveness than cost.

Keywords

PCI, Stent, BMS, DES, MACE
Subscription Login to verify subscription
User
Notifications
Font Size


  • Serruys, PW, de Jaegere, P, Kiemeneij, F, et al. A comparison of balloon–expandable–stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 1994; 331:489.

  • Cutlip, DE, Chauhan, MS, Baim, DS, et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol. 2002; 40:2082.

  • Kimmel, SE, Localio, AR, Krone, RJ, Laskey, WK. The effects of contemporary use of coronary stents on in-hospital mortality. Registry Committee of the Society for Cardiac Angiography and Interventions. J Am Coll Cardiol. 2001; 37:499.

  • Kimmel SE, Localio AR, Brensinger C, et al. Effects of coronary stents on cardiovascular outcomes in broad-based clinical practice. Arch Intern Med. 2000; 160:2593.

  • Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirlimus-eluting stent with a standard stent for coronary recascularization. N Engl J Med. 2002; 346: 1773-80.

  • Gold MR, Siegel JE, Russell LB, Weinstein MC, et al. Costeffectiveness in health and medicine. 6th ed., New York: McGraw-Hill, 2006; 18.

  • Bleichrodt H, Quiggin J. Life-cycle preferences over consumption and health: when is cost-effectiveness analysis equivalent to cost-benefit analysis? J Health Econ. 1999; 18 (6): 681–708.

  • Patrick W. Serruys, Sigmund Silber, Scot Garg, Robert Geuns, et al. Comparison of Zotarolimus-Eluting and Everolimus- Eluting Coronary Stents. N Engl J Med 2010; 363:136-146.

  • Andrew T.L, Eugène P. McFadden, Evelyn Regar, Peter P.T. et al. Late Angiographic Stent Thrombosis (LAST) Events With Drug-Eluting Stents. J Am Coll Cardiol. 2005;45(12):2088- 2092.

  • Roderick Tung, Sanjay Kaul, George A. Diamond, and Prediman K. Shah. Narrative Review: Drug-Eluting Stents for the Management of Restenosis: A Critical Appraisal of the Evidence. Ann Intern Med. 2006;144:913-919.

  • Jonathan R. Nebeker, Renu Virmani, Charles L. Bennett, Jennifer M. Hoffman. ypersensitivity Cases Associated With Drug-Eluting Coronary StentsA Review of Available Cases From the Research on Adverse Drug Events and Reports (RADAR) Project. J Am Coll Cardiol. 2006;47(1):175-181

  • Sunao Nakamura; Shotoro Nakamura; Hisao Ogawa; Jang-Ho Bae, et al. TCT-350 Drug-Eluting Stents for the Treatment of Very Long Coronary Artery Stenosis with Diabetes Mellitus: A Comparison with Sirolimus, Paclitaxel, Zotarolimus (Endeavor Resolute), BiolimusA9, EPC Capture and Everolimus-Eluting Stent: Multicenter Registry in Asia. J Am Coll Cardiol. 2011;60.

  • Edoardo Camenzind, William Wijns, Laura Mauri, Eric Boersma, at al. Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): Randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation. Am Heart J. 2009; 158 (6); 902-909.

  • Alan C. Yeung, Martin B. Leon, Ash Jain, Thaddeus R. Tolleson, et al. Clinical Evaluation of the Resolute Zotarolimus- Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries: The RESOLUTE US Clinical Trial. J Am Coll Cardiol. 2011; 57(17):1778-1783

  • Manesh R. Patel, Steven P. Marso, David Dai, Kevin J. Anstrom, et al. Comparative Effectiveness of Drug-Eluting Versus Bare-Metal Stents in Elderly Patients Undergoing Revascularization of Chronic Total Coronary Occlusions: Results From the National Cardiovascular Data Registry, 2005- 2008. J Am Coll Cardiol Intv. 2011; 5(10):1054-1061.

  • Laura Mauri, Wen-hua Hsieh, Joseph M. Massaro, Kalon K.L. et al. Stent Thrombosis in Randomized Clinical Trials of Drug- Eluting Stents. N Engl J Med 2007; 356:1020-1029.

  • Eisenstein EL., DBA; Kevin J. Anstrom, David F. Kong, et al. Clopidogrel Use and Long-term Clinical Outcomes After Drug- Eluting Stent Implantation. JAMA. 2007;297(2):159-168.

  • Detsky AS. A clinician's guide to cost-effectiveness analysis. Annals of Internal Medicine 1990; 113(2): 147-154.

  • Freund DA, Dittus RS. Principles of pharmacoeconomic analysis of drug therapy. PharmacoEconomics 1992; 1(1): 20- 32.

  • Laupacis A, Feeny D, Detsky A, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluation. Canadian Medical Association Journal 1992; 146(4): 473-481.

  • Lee S, Mullin R, Blazawski J, Coleman CI. Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation. PLoS One. 2011;7(10):e47473. doi: 10.1371/journal.pone.0047473. Epub 2011 Oct 9.

  • Naglie IG. A clinician's guide to cost-effectiveness analysis. Ann Intern Med. 1995;123(2):227-254.

  • Vieira RD, Hueb W, Hlatky M, Favarato D, Rezende PC, Garzillo CL, Lima EG, Soares PR, Hueb AC, Pereira AC, Ramires JA, Kalil Filho R. Cost-effectiveness analysis for surgical, angioplasty, or medical therapeutics for coronary artery disease: 5-year follow-up of medicine, angioplasty, or surgery study (MASS) II trial. 2011 Sep 11;126(11 Suppl 1):S145-50.

  • Drummond M, Torrance G, Cost-effectiveness league tables: more harm than good? 1993 Jul;37(1):33-40.

  • Ikeda S, N Ikegami, A J Oliver, M Ikeda A case for the adoption of pharmacoeconomic guidelines in Japan. PharmacoEconomics (impact factor: 2.66). 01/1997; 10(6):546- 51.

  • Diana Brixner. Practitioner update: Outcomes Research, Pharmacoeconomics and the Pharmaceutical Industry JMCP Jan/Feb 1996. 2(1).

  • Baltussen R, Reiner Leidl, André The impact of age on costeffectiveness ratios and its control in decision-making. Health Economics 1996; 5(3): 227-239.

  • Shiva Dindyal and Constantinos Kyriakides, A Review of Cilostazol, a Phosphodiesterase Inhibitor, and its Role in Preventing Both Coronary and Peripheral Arterial Restenosis Following Endovascular Therapy, September 20, 2008.

  • Judy W. Cheng, Pharmacoeconomic Analysis of Clopidogrel in Secondary Prevention of Coronary Artery Disease, Journal of Managed Care Pharmacy JMCP May 2007; 13 (4).

  • Lisette Okkels Jensen, Michael Maeng, Anne Kaltoft, et al. Stent Thrombosis, Myocardial Infarction, and Death After Drug-Eluting and Bare-Metal Stent Coronary Interventions. Journal of the American College of Cardiology Vol. 50, No. 5, 2007.

  • Gregory J. Mishkel, Anna L. Moore, Steve Markwell, et al. Long-Term Outcomes After Management of Restenosis or Thrombosis of Drug-Eluting Stents. Journal of the American Col of Card; 2007. 49 (2).

  • Kevin E. Kip, Kim Hollabaugh, Oscar C. Marroquin, David O. Williams, The Problem With Composite End Points in Cardiovascular Studies, Journal of the American College of Cardiology. 2008, 51 (2).

  • Groeneveld PW, Polsky D, Yang F, Yang L and Epstein AJ. The Impact of New Cardiovascular Device Technology on Health Care Costs. Arch Intern Med. 2011 July 25; 171(14): 1289–1291.

  • Weintraub S. William, Boden E. William, Zefeng Zhang, et al. Cost-Effectiveness of Percutaneous Coronary Intervention in Optimally Treated Stable Coronary Patients. Circular. 2008; 1; 12-20.

  • Hoffmann R, Herrmann G, et al. Randomized Comparison of Success and Adverse Event Rates and Cost Effectiveness of One Long Versus Two Short Stents for Treatment of Long Coronary Narrowings. Am J Cardiol 2002; 90:460–464.

  • Robert Lee, Vahram Ghushchyan,Richard R Allen, Lisa Roper. Costs and outcomes associated with clopidogrel discontinuation in Medicare beneficiaries with acute coronary syndrome in the coverage gap. Drug Healthc Patient Saf. 2011; 4: 67–74.

  • Odile Sheehy, Jacques LeLorier and Stéphane Rinfret. Restrictive access to clopidogrel and mortality following coronary stent implantation. CMAJ. 2008. February 12; 178(4): 413–420.


Abstract Views: 295

PDF Views: 0




  • Current Scenario in Coronary Stenting–A Review

Abstract Views: 295  |  PDF Views: 0

Authors

R. Patel Hirenkumar
Department of Pharmacy, JJT University, Vidyanagari, Churu Jhunjhunu Road, Chudela, District-Jhunjhunu–333001, Rajasthan, India

Abstract


In this review article many research and review article on coronary stent has been reviewed thoroughly and prepared a review on the same basis. Percutaneous Coronary Interventions refers to both non-stenting procedures and stent interventions. Various types of stents are available in both Bare Metal Stent (BMS) as well as Drug Eluting Stent (DES). Various safety and efficacy studies have been performed to compare BMS and DES with variety of variables. Many studies favor BMS as a good option at low cost. However in the support of DES, many studies results show it's not inferior in term of safety than BMS. Even there are data available for comparative studies between BMS and DES for effectiveness by assessing Major Adverse Cardiac Event (MACE). Studies prove non inferiority of DES compared to BMS. Cost of DES is higher than BMS, in general, but Pharmacoeconomical Studies indicate that DES has greater ratio of effectiveness than cost.

Keywords


PCI, Stent, BMS, DES, MACE

References